ITLN1 and colorectal carcinoma: Notably, a monotonic dose-response relationship was observed: participants in the highest omentin quartile (median ≈ 563 ng/mL) had a 2.3-fold higher CRC risk than those in the lowest quartile (≈287 ng/mL), and each doubling of omentin-1 was associated with nearly a two-fold increase in relative risk (RR ≈ 1.98).